Skip to main content
Fig. 6 | Clinical Epigenetics

Fig. 6

From: Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Fig. 6

The antitumor activity of combination MPT0E028 with PD98059 in human pancreatic cancer xenograft model. AsPC-1 cells were transplanted subcutaneously in Balb/c-nude mice. Mice were randomized into four groups with daily treatment: vehicle control, MPT0E028 (oral, 25 mg/kg), PD98059 (intraperitoneal (ip), 20 mg/kg), or combinational therapy. Tumor volume of AsPC-1 xenograft was shown in a and the body weights were revealed in b. *P < 0.05 and **P < 0.01 compared with the respective control group. c Tumor protein lysates were subjected to immunoblot with caspase-3 antibody. Actin was served as a loading control. d Hematoxylin and eosin staining was performed to examine cell morphology, and the immunohistochemical staining determines the expressions of cleavage caspase-3 and EGFR before or after indicated drug treatment. PD PD98059, E MPT0E028

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us